Long-term outcome of intravitreal anti-vascular endothelial growth factor treatment for pachychoroid neovasculopathy

Abstract To compare the long-term effectiveness of intravitreal anti-vascular endothelial growth factor (VEGF) treatment for pachychoroid neovasculopathy (PNV), polypoidal choroidal vasculopathy/aneurysmal type 1 neovascularization (PCV/AT1), and typical neovascular age-related macular degeneration...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jihyun Yoon, Wontae Yoon, Seung kwan Na, Jihyun Lee, Chul Gu Kim, Jong Woo Kim, Han Joo Cho
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/44ab98d1b6fa4b17aac53023fb8539a3
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:44ab98d1b6fa4b17aac53023fb8539a3
record_format	dspace
spelling	oai:doaj.org-article:44ab98d1b6fa4b17aac53023fb8539a32021-12-02T17:47:23ZLong-term outcome of intravitreal anti-vascular endothelial growth factor treatment for pachychoroid neovasculopathy10.1038/s41598-021-91589-22045-2322https://doaj.org/article/44ab98d1b6fa4b17aac53023fb8539a32021-06-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-91589-2https://doaj.org/toc/2045-2322Abstract To compare the long-term effectiveness of intravitreal anti-vascular endothelial growth factor (VEGF) treatment for pachychoroid neovasculopathy (PNV), polypoidal choroidal vasculopathy/aneurysmal type 1 neovascularization (PCV/AT1), and typical neovascular age-related macular degeneration (nAMD). Forty-one eyes with PNV, 68 eyes with PCV/AT1, and 56 eyes with typical nAMD were retrospectively included for analysis. All patients were treatment-naïve and received a three-monthly loading injection of anti-VEGF, followed by further injections, as required. The visual and anatomical outcomes after treatment were evaluated up to 36 months from baseline. No significant intergroup difference was found in terms of best-corrected visual acuity (BCVA) and changes in central foveal thickness at 12, 24, and 36 months after the baseline. In addition, no significant difference was found between the groups regarding the proportions of improved or worsened (increased or decreased more than 3-lines) visual acuity. However, the PNV group participants received significantly fewer anti-VEGF injections (11.7 ± 6.9) than those in the PCV/AT1 (12.4 ± 7.0; P = 0.031) and typical nAMD groups (13.2 ± 7.4; P = 0.016). The incidence of macular atrophy (MA) development was also significantly lower for the PNV (4/41 eyes, 9.8%) than the typical nAMD (15/56 eyes, 26.8%; P = 0.033) eyes. There was no significant difference between PNV, PCV/AT1, and typical nAMD regarding visual acuity improvement after anti-VEGF treatment over 36 months. However, the number of injections for PNV was significantly lower compared to that for PCV/AT1 and typical nAMD, and the incidence of MA development was significantly lower than in typical nAMD.Jihyun YoonWontae YoonSeung kwan NaJihyun LeeChul Gu KimJong Woo KimHan Joo ChoNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-8 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Jihyun Yoon Wontae Yoon Seung kwan Na Jihyun Lee Chul Gu Kim Jong Woo Kim Han Joo Cho Long-term outcome of intravitreal anti-vascular endothelial growth factor treatment for pachychoroid neovasculopathy
description	Abstract To compare the long-term effectiveness of intravitreal anti-vascular endothelial growth factor (VEGF) treatment for pachychoroid neovasculopathy (PNV), polypoidal choroidal vasculopathy/aneurysmal type 1 neovascularization (PCV/AT1), and typical neovascular age-related macular degeneration (nAMD). Forty-one eyes with PNV, 68 eyes with PCV/AT1, and 56 eyes with typical nAMD were retrospectively included for analysis. All patients were treatment-naïve and received a three-monthly loading injection of anti-VEGF, followed by further injections, as required. The visual and anatomical outcomes after treatment were evaluated up to 36 months from baseline. No significant intergroup difference was found in terms of best-corrected visual acuity (BCVA) and changes in central foveal thickness at 12, 24, and 36 months after the baseline. In addition, no significant difference was found between the groups regarding the proportions of improved or worsened (increased or decreased more than 3-lines) visual acuity. However, the PNV group participants received significantly fewer anti-VEGF injections (11.7 ± 6.9) than those in the PCV/AT1 (12.4 ± 7.0; P = 0.031) and typical nAMD groups (13.2 ± 7.4; P = 0.016). The incidence of macular atrophy (MA) development was also significantly lower for the PNV (4/41 eyes, 9.8%) than the typical nAMD (15/56 eyes, 26.8%; P = 0.033) eyes. There was no significant difference between PNV, PCV/AT1, and typical nAMD regarding visual acuity improvement after anti-VEGF treatment over 36 months. However, the number of injections for PNV was significantly lower compared to that for PCV/AT1 and typical nAMD, and the incidence of MA development was significantly lower than in typical nAMD.
format	article
author	Jihyun Yoon Wontae Yoon Seung kwan Na Jihyun Lee Chul Gu Kim Jong Woo Kim Han Joo Cho
author_facet	Jihyun Yoon Wontae Yoon Seung kwan Na Jihyun Lee Chul Gu Kim Jong Woo Kim Han Joo Cho
author_sort	Jihyun Yoon
title	Long-term outcome of intravitreal anti-vascular endothelial growth factor treatment for pachychoroid neovasculopathy
title_short	Long-term outcome of intravitreal anti-vascular endothelial growth factor treatment for pachychoroid neovasculopathy
title_full	Long-term outcome of intravitreal anti-vascular endothelial growth factor treatment for pachychoroid neovasculopathy
title_fullStr	Long-term outcome of intravitreal anti-vascular endothelial growth factor treatment for pachychoroid neovasculopathy
title_full_unstemmed	Long-term outcome of intravitreal anti-vascular endothelial growth factor treatment for pachychoroid neovasculopathy
title_sort	long-term outcome of intravitreal anti-vascular endothelial growth factor treatment for pachychoroid neovasculopathy
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/44ab98d1b6fa4b17aac53023fb8539a3
work_keys_str_mv	AT jihyunyoon longtermoutcomeofintravitrealantivascularendothelialgrowthfactortreatmentforpachychoroidneovasculopathy AT wontaeyoon longtermoutcomeofintravitrealantivascularendothelialgrowthfactortreatmentforpachychoroidneovasculopathy AT seungkwanna longtermoutcomeofintravitrealantivascularendothelialgrowthfactortreatmentforpachychoroidneovasculopathy AT jihyunlee longtermoutcomeofintravitrealantivascularendothelialgrowthfactortreatmentforpachychoroidneovasculopathy AT chulgukim longtermoutcomeofintravitrealantivascularendothelialgrowthfactortreatmentforpachychoroidneovasculopathy AT jongwookim longtermoutcomeofintravitrealantivascularendothelialgrowthfactortreatmentforpachychoroidneovasculopathy AT hanjoocho longtermoutcomeofintravitrealantivascularendothelialgrowthfactortreatmentforpachychoroidneovasculopathy
_version_	1718379462433701888

Long-term outcome of intravitreal anti-vascular endothelial growth factor treatment for pachychoroid neovasculopathy

Ejemplares similares